List of Excipients in Branded Drug ESTRADIOL VAGINAL INSERTS

Generic Drugs Containing ESTRADIOL VAGINAL INSERTS

Company	Ingredient	NDC	Excipient
Aurobindo Pharma Limited	estradiol	59651-439	HYPROMELLOSE 2208
Aurobindo Pharma Limited	estradiol	59651-439	HYPROMELLOSE 2910
Aurobindo Pharma Limited	estradiol	59651-439	LACTOSE MONOHYDRATE
Aurobindo Pharma Limited	estradiol	59651-439	MAGNESIUM STEARATE
Aurobindo Pharma Limited	estradiol	59651-439	STARCH, CORN
Glenmark Pharmaceuticals Inc USA	estradiol	68462-711	HYPROMELLOSE
Glenmark Pharmaceuticals Inc USA	estradiol	68462-711	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in ESTRADIOL VAGINAL INSERTS?

# Of NDCs	Excipient
1	HYPROMELLOSE
2	HYPROMELLOSE 2208
2	HYPROMELLOSE 2910
3	LACTOSE MONOHYDRATE
3	MAGNESIUM STEARATE
1	POLYETHYLENE GLYCOL
1	SILICON DIOXIDE

Estradiol Vaginal Inserts: Excipient Strategy, Patent Exposure, and Commercial Opportunities

Last updated: August 2, 2026

Estradiol vaginal inserts are a specialized low-dose estrogen platform in which excipient selection affects drug release, leakage, patient comfort, manufacturing cost, and generic substitutability. The leading U.S. product, Imvexxy, uses a softgel vaginal insert containing 4 mcg or 10 mcg of estradiol. Its commercial opportunity is concentrated in postmenopausal vulvar and vaginal atrophy, now commonly addressed within the broader genitourinary syndrome of menopause market.

The strongest excipient opportunities are preservative-free delivery, improved vaginal retention, lower-cost shell systems, room-temperature stability, and differentiated inserts that reduce mess and dosing variability. The principal commercial risks are generic entry, limited systemic exposure that constrains clinical differentiation, and competition from estradiol tablets, creams, rings, and newer non-estrogen products.

What is the estradiol vaginal insert market?

Estradiol vaginal inserts deliver low doses of estradiol directly to vaginal tissue. U.S. products are approved for moderate-to-severe symptoms of vulvar and vaginal atrophy caused by menopause, including vaginal dryness and dyspareunia.

Product	Active ingredient	Dose	Dosage form	Key commercial company	FDA status
Imvexxy	Estradiol	4 mcg and 10 mcg	Softgel vaginal insert	Mayne Pharma commercial portfolio; originally developed by TherapeuticsMD	FDA-approved
Vagifem generics and branded Vagifem	Estradiol hemihydrate	10 mcg	Vaginal tablet with applicator	Novo Nordisk and generic manufacturers	FDA-approved
Estrace vaginal cream and generics	Estradiol	0.01% cream	Vaginal cream	Multiple manufacturers	FDA-approved
Estring	Estradiol	7.5 mcg/day release rate	Vaginal ring	Pfizer	FDA-approved
Femring	Estradiol acetate	0.05 mg/day or 0.10 mg/day	Vaginal ring	Warner Chilcott legacy product	FDA-approved

Imvexxy was approved by the FDA in 2018 under NDA 208643. The product uses an applicator-free insert, a positioning advantage over tablet products that require an applicator. The 4 mcg strength is positioned for lower-dose therapy, while the 10 mcg strength competes more directly with Vagifem 10 mcg. [1]

The addressable market includes women seeking local treatment with limited systemic estrogen exposure. The product can also benefit from the broader expansion of menopause treatment awareness, although prescribing remains sensitive to boxed-warning language and patient concerns about estrogen therapy.

What excipients are used in estradiol vaginal inserts?

The Imvexxy dosage form is a small softgel capsule. Public labeling identifies hard fat, gelatin, glycerin, and titanium dioxide among the inactive ingredients. The formulation uses the capsule shell and lipid-based fill to deliver a very low estradiol dose without a traditional cream or aqueous gel vehicle. [2]

Formulation component	Likely function	Commercial relevance
Hard fat	Lipid vehicle and release matrix	Supports a small insert and hydrophobic estradiol dispersion
Gelatin	Softgel shell	Enables unit-dose containment and vaginal insertion
Glycerin	Plasticizer and humectant	Controls shell flexibility and handling characteristics
Titanium dioxide	Opacifier and color control	Supports product appearance and light protection
Estradiol	Active pharmaceutical ingredient	Low-dose local estrogen therapy

The formulation strategy has several technical consequences:

1. It avoids preservatives commonly used in aqueous creams.
2. It provides a compact unit dose without an applicator.
3. It uses a lipid system that may improve estradiol compatibility and content uniformity.
4. It shifts manufacturing complexity to softgel encapsulation, shell moisture control, fill viscosity, and capsule integrity.
5. It creates potential differences in dissolution and vaginal dispersion compared with tablets and creams.

The public label does not establish that every excipient is responsible for clinical performance. Excipient function must be separated from patent claim scope, which may cover composition, capsule structure, manufacturing, dosage strength, or use.

How does excipient selection affect product performance?

Hard-fat lipid systems

Hard fat is a practical carrier for a very low dose of estradiol because it can produce a compact, nonaqueous insert. The lipid matrix can limit dusting and support uniform drug distribution during encapsulation.

Key development variables include:

• Estradiol particle size and dispersion.
• Homogeneity of the fill material.
• Melting and solidification behavior.
• In vitro release in simulated vaginal fluid.
• Leakage after exposure to vaginal temperature.
• Interaction between fill and gelatin shell.
• Long-term oxidation and moisture stability.

A hard-fat system may produce a slower or less predictable release profile than a rapidly disintegrating tablet. That distinction can create an opportunity for a follow-on product with improved tissue exposure or reduced residue, but it can also increase bioequivalence risk.

Gelatin shell systems

Gelatin is widely used in softgels because it provides mechanical strength, sealing performance, and a familiar manufacturing pathway. For a vaginal product, shell performance must account for:

• Softening at body temperature.
• Rapid hydration and rupture.
• Mechanical handling during insertion.
• Compatibility with vaginal moisture.
• Stability under high humidity.
• Microbial control during manufacture.

Gelatin can present supply-chain and formulation constraints. It is animal-derived, which can limit suitability for some patients and markets. It also requires tighter control of water activity and shell moisture than many polymeric alternatives.

Glycerin and shell plasticization

Glycerin improves flexibility and reduces brittleness. Excessive plasticization can increase tackiness, deformation, or leakage. Insufficient plasticization can create cracking during packaging or insertion.

A reformulated product using sorbitol, alternative polyols, or non-gelatin polymers could target improved handling and reduced humidity sensitivity. Such a change would require comparative stability and performance data, and it could trigger a new drug product development pathway rather than a simple formulation change.

Titanium dioxide and color systems

Titanium dioxide is generally used for opacity and appearance rather than therapeutic performance. A manufacturer seeking a cleaner-label or global formulation could assess alternative opacifiers or omit the colorant where light protection is not necessary.

The commercial value of this change is modest unless it improves consumer acceptance, regulatory positioning, or supply continuity. It is unlikely to create strong differentiation by itself.

What formulation patents protect estradiol vaginal inserts?

Patent protection for estradiol vaginal inserts can extend beyond the active ingredient. The relevant claim categories typically include:

• A low-dose estradiol insert for treating vulvovaginal atrophy.
• A softgel capsule containing estradiol in a lipid or fatty-acid vehicle.
• Specific estradiol strengths, including 4 mcg and 10 mcg.
• Capsule dimensions and vaginal administration methods.
• Pharmacokinetic or local-treatment characteristics.
• Manufacturing processes for producing a uniform low-dose fill.
• Packaging and applicator-free administration.
• Use in patients with dyspareunia, dryness, or other menopausal symptoms.

The underlying estradiol molecule is generic and long off patent. Competitive protection therefore depends on formulation, dosage form, method of use, and regulatory exclusivity rather than molecule-level exclusivity.

The Orange Book listing for Imvexxy must be evaluated patent by patent because the commercial exposure depends on listed claims, expiration dates, pediatric exclusivity, patent-term adjustment, and any applicable regulatory exclusivity. FDA Orange Book records identify patents submitted by the NDA holder, but they do not independently determine whether each patent will block a specific generic product. [3]

A serious freedom-to-operate analysis should compare each listed claim against:

• The generic’s shell composition.
• The lipid or nonlipid vehicle.
• Drug loading and strength.
• Capsule dimensions.
• Dissolution profile.
• Labeling and method-of-use language.
• Manufacturing process.
• Proposed ANDA certification.

When does estradiol vaginal insert exclusivity expire?

Estradiol vaginal inserts do not have new chemical entity exclusivity because estradiol is an established active ingredient. Imvexxy received approval through the 505(b)(2) pathway rather than as a new chemical entity. Commercial exclusivity therefore depends mainly on patents and any limited regulatory protections attached to the approved application. [1]

Exclusivity category	Relevance to estradiol vaginal inserts
New chemical entity exclusivity	Generally unavailable because estradiol is an old active ingredient
Orphan exclusivity	Not applicable to the approved indication
Pediatric exclusivity	Depends on FDA-awarded studies and current regulatory records
505(b)(2) exclusivity	May apply in limited circumstances, but does not create molecule-level protection
Orange Book patents	Primary barrier to ANDA entry
Formulation and method-of-use claims	Potentially material through patent expiry

The practical loss-of-exclusivity date is the earliest date on which a commercially viable generic can launch after accounting for patent challenges, settlement terms, litigation outcomes, regulatory review, and any applicable pediatric extension. Patent expiry should not be treated as equivalent to automatic generic launch.

What Paragraph IV challenges and litigation risks affect Imvexxy?

A generic applicant can file an ANDA with a Paragraph IV certification asserting that an Orange Book-listed patent is invalid, unenforceable, or not infringed. The NDA holder can then file an infringement action within 45 days, potentially triggering a 30-month stay of FDA approval under the Hatch-Waxman framework. [4]

For Imvexxy, the central litigation questions would likely concern whether a proposed generic:

• Uses the same or substantially similar softgel architecture.
• Falls within claims covering hard fat or another lipid vehicle.
• Meets a claimed estradiol concentration range.
• Practices a patented method of treating vulvovaginal atrophy.
• Uses a manufacturing process covered by an issued patent.
• Can design around shell composition or capsule geometry.

A non-infringing generic could avoid some formulation claims by using a tablet, polymeric insert, or different capsule shell. That strategy may increase development cost and create a more difficult bioequivalence package.

No biosimilar pathway applies. Estradiol is a chemically synthesized small molecule, so competitive entrants would use an ANDA, 505(b)(2) application, or full NDA rather than a biologics license application.

What are the main excipient opportunities?

Preservative-free alternatives

Preservative-free delivery is already a strength of unit-dose inserts. A follow-on product could extend that advantage with an alternative shell or polymer system that reduces excipient count and addresses patients who report irritation from creams or preservatives.

Non-gelatin soft capsules

Vegetarian or non-animal capsule materials could support differentiated positioning. Candidate systems include modified starch, pullulan, hydroxypropyl methylcellulose, and other film-forming polymers.

The main technical barriers are:

• Shell sealing.
• Moisture transfer.
• Fill compatibility.
• Mechanical strength.
• Rapid vaginal disintegration.
• Scale-up economics.

A non-gelatin insert could also support geographic expansion in markets with religious, dietary, or animal-origin restrictions.

Mucoadhesive inserts

Mucoadhesive polymers could reduce leakage and improve residence time. Examples include carbomers, polycarbophil, cellulose derivatives, hyaluronic-acid-based systems, and selected thiolated polymers.

The commercial risk is excessive adhesion, delayed clearance, irritation, or a foreign-body sensation. For a low-dose hormone, prolonged retention is useful only if it improves local exposure without increasing systemic absorption or patient discomfort.

Bioadhesive tablets and films

A tablet or film can reduce manufacturing cost relative to softgel encapsulation. Thin films may offer rapid hydration, precise dosing, and compact packaging. However, they may be harder to handle and may require an applicator or a more complex insertion method.

The key development target is a release profile that matches the reference product without replicating its exact excipient composition.

Long-acting inserts

A longer-acting estradiol insert could compete with Estring and reduce dosing frequency. Potential systems include biodegradable polymer matrices, osmotic systems, reservoir inserts, and bioadhesive devices.

This opportunity has a higher regulatory burden because the product would no longer be a simple substitute for a daily or twice-weekly insert. Dose dumping, retention, removal, systemic exposure, and local tolerability would require extensive characterization.

Improved stability systems

Excipient and packaging changes can target:

• Reduced estradiol oxidation.
• Lower shell moisture migration.
• Improved high-temperature stability.
• Lower sensitivity to humidity.
• Better resistance to deformation.
• Longer shelf life.

Aluminum blister packaging, high-barrier films, and desiccant-supported secondary packaging may offer commercial value without changing the formulation.

How does Imvexxy compare with Vagifem, Estrace cream, and Estring?

Attribute	Imvexxy	Vagifem	Estrace cream	Estring
Primary form	Softgel insert	Tablet	Cream	Ring
Typical use frequency	Daily initiation, then twice weekly	Daily initiation, then twice weekly	Variable, often more frequent	Replaced approximately every 90 days
Applicator	No applicator required	Applicator generally used	Applicator commonly used	Insertion and removal required
Preservative exposure	Unit-dose softgel platform	Tablet excipients	Cream excipients may include preservatives or stabilizers depending on product	Polymer ring
Leakage or residue	Generally low-volume insert	Tablet residue possible	Higher mess potential	Continuous device
Manufacturing complexity	Softgel encapsulation	Tablet compression and coating	Semisolid manufacture and filling	Polymer device manufacture
Generic substitution risk	Formulation and bioequivalence complexity	Tablet competition is established	Multiple generic products	Device and drug-device complexity

Imvexxy’s strongest commercial differentiator is convenience without an applicator. Its main weakness is that a softgel insert can be more difficult to copy than a conventional tablet but may have higher manufacturing and quality-control costs.

Which companies are challenging the estradiol vaginal insert market?

The competitive landscape includes:

• Novo Nordisk, through Vagifem and related vaginal estrogen products.
• Pfizer, through Estring.
• Manufacturers of generic estradiol vaginal tablets.
• Manufacturers of generic estradiol creams.
• Specialty menopause companies developing non-estrogen therapies.
• Compounding pharmacies, which can supply alternative dosage forms but do not provide the same FDA-approved substitution pathway.

Non-estrogen competitors include ospemifene and prasterone, which address vaginal atrophy through different pharmacologic mechanisms. These products compete for patients who prefer to avoid estrogen or who have treatment restrictions.

The most credible generic threat to a softgel insert may come from a non-identical dosage form that demonstrates equivalent local performance, rather than from a direct copy of the reference softgel.

What FDA regulatory pathway applies to a new estradiol insert?

A product intended to substitute for an approved estradiol vaginal insert may use an ANDA if it can establish pharmaceutical equivalence and bioequivalence. A materially different dosage form, strength, route-specific performance profile, or clinical claim may require a 505(b)(2) application.

The main regulatory issues are:

• Pharmaceutical equivalence.
• Estradiol assay and content uniformity.
• In vitro release and dissolution.
• Comparative pharmacokinetics.
• Local vaginal exposure.
• Systemic estradiol exposure.
• Vaginal irritation and tolerability.
• Stability under long-term and accelerated conditions.
• Container-closure integrity.
• Applicator or insertion-device performance, if used.

Because local vaginal products can produce limited and variable systemic exposure, conventional plasma pharmacokinetics may not fully characterize local equivalence. FDA product-specific guidance and consultation with the agency are important components of development planning. [5]

How strong is the patent estate for estradiol vaginal inserts?

The estate is strongest when claims cover the complete product architecture: low-dose estradiol, a defined lipid fill, a specific softgel shell, a defined release profile, and a method of treating menopausal vaginal symptoms.

The estate is weaker where claims are narrow and easy to design around through:

• A different shell polymer.
• A nonlipid vehicle.
• A tablet or film dosage form.
• A different capsule geometry.
• A different strength outside the claimed range.
• A non-identical method-of-use label.
• A distinct manufacturing process.

Patent strength should be scored across four dimensions:

Factor	Strong position	Weaker position
Claim breadth	Covers multiple shell and vehicle systems	Covers one narrow composition
Design-around burden	Requires a new dosage form or clinical program	Requires only excipient substitution
Regulatory linkage	Patent claims match the reference product	Patent claims are difficult to connect to ANDA labeling
Litigation leverage	Clear infringement and commercial importance	Uncertain claim construction or weak validity

The active ingredient itself contributes little patent strength. The commercial value lies in formulation know-how, manufacturing reproducibility, regulatory data, and brand penetration.

What licensing and partnership opportunities exist?

Licensing opportunities are most attractive in five areas:

1. Regional commercialization rights for approved vaginal estrogen products.
2. Non-gelatin softgel technology compatible with low-dose hormones.
3. Mucoadhesive or long-acting vaginal delivery platforms.
4. High-barrier packaging and stability technologies.
5. Generic formulation platforms that can avoid listed patent claims.

A specialty pharmaceutical company could license an improved insert to a menopause-focused commercial partner. A contract development and manufacturing organization could offer a turnkey package covering formulation, softgel encapsulation, analytical methods, and regulatory support.

The most defensible deal structure would link milestones to formulation feasibility, pilot-scale manufacturing, bioequivalence, ANDA or 505(b)(2) acceptance, and commercial launch. Royalty economics would depend more on market exclusivity and manufacturing cost than on the price of estradiol API.

What generic launch scenarios exist?

Scenario 1: Direct softgel generic

This approach offers the closest patient and prescriber substitution. It also creates the highest risk of formulation patent litigation and the greatest need to match capsule performance.

Scenario 2: Tablet or film alternative

A different dosage form may reduce infringement exposure and manufacturing cost. The regulatory burden can increase if the product cannot demonstrate equivalence through routine ANDA methods.

Scenario 3: 505(b)(2) differentiated insert

A company could pursue a different strength, dosing frequency, shell, or retention profile. This route may support new labeling but requires more clinical and regulatory investment.

Scenario 4: Premium reformulation

A preservative-free, non-gelatin, low-leakage, or long-acting product could command a premium if it improves adherence or patient acceptance. The product would compete on convenience rather than price.

What revenue exposure does the patent estate create?

Revenue exposure depends on:

• Imvexxy net sales and payer coverage.
• The percentage of prescriptions vulnerable to generic substitution.
• The number of viable generic applicants.
• The timing of Paragraph IV filings.
• Settlement restrictions.
• Pharmacy benefit manager formulary decisions.
• The ability of the brand to retain patients through convenience and packaging.

Estradiol vaginal products are generally lower-priced than systemic hormone products and face generic pricing pressure. A successful generic could produce rapid price erosion because the indication is mature and multiple alternative estrogen products already exist.

The brand can defend revenue through:

• Applicator-free administration.
• Patient adherence programs.
• Strong coverage positioning.
• Convenience-oriented packaging.
• Lower-dose differentiation.
• Evidence supporting local symptom relief.
• Reformulations that are difficult to copy under an ANDA.

Key Takeaways

• Imvexxy is a low-dose estradiol softgel vaginal insert approved in 4 mcg and 10 mcg strengths.
• Its public excipient strategy uses hard fat, gelatin, glycerin, and titanium dioxide.
• The main technical value lies in low-dose uniformity, compact delivery, preservative avoidance, and applicator-free administration.
• Estradiol itself has little remaining molecule-level protection; formulation, method-of-use, manufacturing, and dosage-form patents drive exclusivity.
• The most credible generic strategies include direct softgel replication, tablet or film design-arounds, and 505(b)(2) reformulations.
• Commercial opportunities exist for non-gelatin shells, mucoadhesive inserts, long-acting systems, improved stability, and lower-cost manufacturing.
• Generic risk is material because estradiol is a mature active ingredient with established competing dosage forms.
• The strongest differentiated product would improve retention, comfort, dosing convenience, or shelf stability without increasing systemic exposure.

FAQs

Can a generic estradiol vaginal insert use different excipients?

Yes. An ANDA applicant can use different inactive ingredients if the product meets applicable equivalence, safety, performance, and regulatory requirements. Different excipients may increase bioequivalence and formulation-development risk.

Is hard fat essential for estradiol vaginal insert performance?

No. Hard fat is a useful lipid vehicle, but alternative lipid, polymeric, tablet, film, or softgel systems may be technically feasible. The substitute must provide acceptable drug uniformity, release, stability, and vaginal tolerability.

Are estradiol vaginal inserts considered biologics?

No. Estradiol is a chemically synthesized small molecule. Follow-on products generally use the ANDA or 505(b)(2) pathways rather than the biosimilar pathway.

Can a new insert avoid Imvexxy patents by changing the capsule shell?

Possibly, but shell substitution alone may not avoid claims covering the active fill, dosage strength, release characteristics, manufacturing method, or method of use. A complete claim-by-claim freedom-to-operate analysis is required.

Which excipient innovation has the highest commercial potential?

A non-gelatin, low-leakage insert with room-temperature stability and simple applicator-free administration has the clearest commercial rationale. A long-acting system may offer greater differentiation but carries higher clinical, regulatory, and manufacturing risk.

References

1. U.S. Food and Drug Administration. (2018). Imvexxy approval letter and prescribing information, NDA 208643.
2. U.S. National Library of Medicine. (n.d.). DailyMed: Imvexxy estradiol vaginal insert prescribing information.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.
5. U.S. Food and Drug Administration. (n.d.). Product-specific guidances for generic drug development.